These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Deandreis D; Leboulleux S; Dromain C; Auperin A; Coulot J; Lumbroso J; Deschamps F; Rao P; Schlumberger M; de Baère T Radiology; 2011 Jan; 258(1):270-6. PubMed ID: 21045185 [TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787 [TBL] [Abstract][Full Text] [Related]
4. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation. Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226 [TBL] [Abstract][Full Text] [Related]
5. PET/CT-guided percutaneous liver mass biopsies and ablations: targeting accuracy of a single 20 s breath-hold PET acquisition. Shyn PB; Tatli S; Sahni VA; Sadow CA; Forgione K; Mauri G; Morrison PR; Catalano PJ; Silverman SG Clin Radiol; 2014 Apr; 69(4):410-5. PubMed ID: 24411824 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. Langenhoff BS; Oyen WJ; Jager GJ; Strijk SP; Wobbes T; Corstens FH; Ruers TJ J Clin Oncol; 2002 Nov; 20(22):4453-8. PubMed ID: 12431968 [TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET-CT: predicting recurrence in patients following percutaneous cryoablation treatment for stage I primary non-small-cell lung cancer. LoGiurato B; Matthews R; Safaie E; Moore W; Bilfinger T; Relan N; Franceschi D Nucl Med Commun; 2015 Sep; 36(9):908-13. PubMed ID: 25973693 [TBL] [Abstract][Full Text] [Related]
8. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results. Okuma T; Okamura T; Matsuoka T; Yamamoto A; Oyama Y; Toyoshima M; Koyama K; Inoue K; Nakamura K; Inoue Y Ann Nucl Med; 2006 Feb; 20(2):115-21. PubMed ID: 16615420 [TBL] [Abstract][Full Text] [Related]
9. Intraprocedural Ablation Margin Assessment by Using Ammonia Perfusion PET during FDG PET/CT-guided Liver Tumor Ablation: A Pilot Study. Shyn PB; Casadaban LC; Sainani NI; Sadow CA; Bunch PM; Levesque VM; Kim CK; Gerbaudo VH; Silverman SG Radiology; 2018 Jul; 288(1):138-145. PubMed ID: 29613843 [TBL] [Abstract][Full Text] [Related]
10. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound. Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075 [TBL] [Abstract][Full Text] [Related]
11. Predictive value of pattern classification 24 hours after radiofrequency ablation of liver metastases on CT and positron emission tomography/CT. Vandenbroucke F; Vandemeulebroucke J; Ilsen B; Verdries D; Belsack D; Everaert H; Buls N; Ros PR; de Mey J J Vasc Interv Radiol; 2014 Aug; 25(8):1240-9. PubMed ID: 24954606 [TBL] [Abstract][Full Text] [Related]
12. Real-time FDG PET guidance during biopsies and radiofrequency ablation using multimodality fusion with electromagnetic navigation. Venkatesan AM; Kadoury S; Abi-Jaoudeh N; Levy EB; Maass-Moreno R; Krücker J; Dalal S; Xu S; Glossop N; Wood BJ Radiology; 2011 Sep; 260(3):848-56. PubMed ID: 21734159 [TBL] [Abstract][Full Text] [Related]
13. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125 [TBL] [Abstract][Full Text] [Related]
14. Increase in fluorodeoxyglucose positron emission tomography activity following complete radiofrequency ablation of lung tumors. Sharma A; Lanuti M; He W; Palmer EL; Shepard JA; Digumarthy SR J Comput Assist Tomogr; 2013; 37(1):9-14. PubMed ID: 23321827 [TBL] [Abstract][Full Text] [Related]
15. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. Donckier V; Van Laethem JL; Goldman S; Van Gansbeke D; Feron P; Ickx B; Wikler D; Gelin M J Surg Oncol; 2003 Dec; 84(4):215-23. PubMed ID: 14756432 [TBL] [Abstract][Full Text] [Related]
16. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Ryan ER; Sofocleous CT; Schöder H; Carrasquillo JA; Nehmeh S; Larson SM; Thornton R; Siegelbaum RH; Erinjeri JP; Solomon SB Radiology; 2013 Jul; 268(1):288-95. PubMed ID: 23564714 [TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation. Cornelis F; Sotirchos V; Violari E; Sofocleous CT; Schoder H; Durack JC; Siegelbaum RH; Maybody M; Humm J; Solomon SB J Nucl Med; 2016 Jul; 57(7):1052-7. PubMed ID: 26912433 [TBL] [Abstract][Full Text] [Related]
18. Detection of local tumor progression by (18)F-FDG PET/CT following lung radiofrequency ablation: PET versus CT. Suzawa N; Yamakado K; Takao M; Taguchi O; Yamada T; Takeda K Clin Nucl Med; 2013 Apr; 38(4):e166-70. PubMed ID: 23429399 [TBL] [Abstract][Full Text] [Related]
19. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905 [TBL] [Abstract][Full Text] [Related]
20. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]